Reuters logo
a month ago
BRIEF-Newlink Genetics reports positive Phase 1B data for co's IDO pathway inhibitor
June 23, 2017 / 11:18 AM / a month ago

BRIEF-Newlink Genetics reports positive Phase 1B data for co's IDO pathway inhibitor

1 Min Read

June 23 (Reuters) - Newlink Genetics Corp:

* Positive phase 1b data for Newlink Genetics’ IDO pathway inhibitor, indoximod, in combination with chemotherapy for patients with newly diagnosed acute myeloid leukemia (aml) presented at the European Hematologic Association (eha) congress in Madrid, Spain Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below